Pazopanib HCl (GW786034 HCl)

Catalog No.S1035

Pazopanib HCl (GW786034 HCl) Chemical Structure

Molecular Weight(MW): 473.98

Pazopanib HCl (GW786034 HCl) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively.

Size Price Stock Quantity  
In DMSO USD 191 In stock
USD 147 In stock
USD 270 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 7 Publications

3 Customer Reviews

  • IC50 of Pazopanib that block ANDV-induced EC permeability. Endothelial cells were ANDV infected, and 3 days postinfection the permeability of cells in response to VEGF addition was determined in the presence or absence of increasing amounts of kinase inhibitor. (B): VEGFR2-Src inhibitors block ANDV-induced permeability. Endothelial cells were plated on vitronectin-coated Transwell inserts and infected at an MOI of 0.5 in triplicate with ANDV. Three days postinfection, the permeability of ANDV- and mock-infected endothelial cell monolayers was determined at indicated times in the presence or absence of Pazopanib.

    J Virol, 2011, 85(5): 2296-303. Pazopanib HCl (GW786034 HCl) purchased from Selleck.

    Effect of HDIL-2/TKI on apoptosis of RCC cells. Three RCC cell lines treated with different concentrations of Pazopanib and HDIL-2 and incubated for 48 h. Microscopic images show apoptotic materials 48 h following treatment (arrows show the apoptotic materials in the pazopanib-treated cells).

    Expert Opin Pharmacother 2014 15(11), 1489-99. Pazopanib HCl (GW786034 HCl) purchased from Selleck.

  • MRC5 non-transformed human lung fibroblasts were infected with influenza viruses (100 multiplicity of infection). Two hours after infection the cells were treated with vehicle control; sorafenib tosylate (2mM); pazopanib (2mM); OSU-03012 (2mM); and AR-13 (2mM). Twenty-four hours after infection the cells are treated with live/dead agent where green cells are viable and cells staining yellow or red are considered dead. Cells are examined at 10 magnification in a Hermes wide-field microscope (n¼3 SEM) P<0.05 less than vehicle control level of virus-mediated cell killing.

    J Cell Physiol, 2016, 231(10):2286-302.. Pazopanib HCl (GW786034 HCl) purchased from Selleck.

Purity & Quality Control

Choose Selective VEGFR Inhibitors

Biological Activity

Description Pazopanib HCl (GW786034 HCl) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively.
Features A multi-kinase inhibitor.
Targets
VEGFR1 [1]
(Cell-free assay)
VEGFR2 [1]
(Cell-free assay)
VEGFR3 [1]
(Cell-free assay)
FGFR [1]
(Cell-free assay)
PDGFR [1]
(Cell-free assay)
10 nM 30 nM 47 nM 74 nM 84 nM
In vitro

Pazopanib potently inhibits VEGF-induced phosphorylation of VEGFR2 in HUVEC cells with IC50 of 8 nM. [1] Pazopanib shows dose-dependent growth inhibition in all synovial sarcoma cell lines including SYO-1 and HS-SY-II cells. Proliferation of SYO-1 and HS-SY-II cells is inhibited even at 1 µg/mL of Pazopanib and is completely abolished at 5 µg/mL. Pazopanib induces G1 arrest, and thereby suppresses the growth of synovial sarcoma cells. Phosphorylation of Akts, GSK-3β, JNKs, p70 S6 Kinase, and mTOR is suppressed in Pazopanib-treated SYO-1 cells compared with that in the vehicle-treated cells. [2] Pazopanib between 20 m g/mL and 22.5 m g/mL shows an increasing reduction of RPE cell viability. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HUVEC M{XId2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NGjoOZRqdmirYnn0d{B1cGViVlXHSk1qdmS3Y3XkJJBzd2yrZnXyZZRqd25ib3[gTHVXTUO| MVGxPFYzODN6Mh?=
HUVEC NW[0cWdlU2mwYYPlJIF{e2G7 MnywbY5pcWKrdIOgWmVITi2rbnT1Z4VlKHCqb4PwbI9zgWyjdHnvckBw\iCYRVfGVk0zKGmwIFjVWmVEKGOnbHzzJJdqfGhiYX6gTWM2OCCxZjFijNw5KG6P NWL1XYh2OTh4MkCzPFI>
MM MmrlT4lv[XOnIHHzd4F6 NHPLNZdqdmirYnn0d{BXTUeILXnu[JVk\WRicHjvd5Bpd3K7bHH0bY9vKG:oIH\seFE> M1m1e|E4OTZ2M{Oy
MM.1S MnLqS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NXnpPJFGOTBizsznM41N Mn[ybY5pcWKrdIOgUW0hS2WubDDHdo94fGh? MlT5NVcyPjR|M{K=
MM.1R NHrZN|NIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MlTpNVAh|rypL33M NIj2N|hqdmirYnn0d{BOVSCFZXzsJGdzd3e2aB?= MnzxNVcyPjR|M{K=
RPMI MXXHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? Mnj1NVAh|rypL33M MVfpcohq[mm2czDNUUBE\WyuIFfyc5d1cA>? MoXFNVcyPjR|M{K=
Dox40 NFjpfmxIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NHfk[FUyOCEQvHevcWw> NGq0eo1qdmirYnn0d{BOVSCFZXzsJGdzd3e2aB?= MUWxO|E3PDN|Mh?=
INA-6 NWHub|c5T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MXexNEDPxGdxbVy= M3jKe4lvcGmkaYTzJG1OKEOnbHygS5Jwf3Sq NWrsbI9KOTdzNkSzN|I>
OPM2 NVXIc4drT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MmTnNVAh|rypL33M M2LZN4lvcGmkaYTzJG1OKEOnbHygS5Jwf3Sq NH35fIMyPzF4NEOzNi=>
U266 NYfzcodTT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NUnWbIszOTBizsznM41N NG\yT5RqdmirYnn0d{BOVSCFZXzsJGdzd3e2aB?= MkTpNVcyPjR|M{K=
MM.1S M1LTNoN6fG:2b4jpZ4l1gSCjc4PhfS=> MkC5NlAh|rypL33M NWnzfnNxcW6qaXLpeJMhVU1iQ3XscEBUfXK4aY\hcC=> MWmxO|E3PDN|Mh?=
MM.1R NF\RZY5kgXSxdH;4bYNqfHliYYPzZZk> NUfDTI92OjBizsznM41N NVfTfFFOcW6qaXLpeJMhVU1iQ3XscEBUfXK4aY\hcC=> MkTINVcyPjR|M{K=
RPMI NIraXVlkgXSxdH;4bYNqfHliYYPzZZk> NHvhbZUzOCEQvHevcWw> MVjpcohq[mm2czDNUUBE\WyuIGP1dpZqfmGu NIHxRnUyPzF4NEOzNi=>
Dox40 NWTC[Jh6[3m2b4TvfIlkcXS7IHHzd4F6 Mle5NlAh|rypL33M MXTpcohq[mm2czDNUUBE\WyuIGP1dpZqfmGu NEnaeFUyPzF4NEOzNi=>
INA-6 NWrKdplN[3m2b4TvfIlkcXS7IHHzd4F6 MYCyNEDPxGdxbVy= MYXpcohq[mm2czDNUUBE\WyuIGP1dpZqfmGu NFywS3YyPzF4NEOzNi=>
OPM2 NFTFW5lkgXSxdH;4bYNqfHliYYPzZZk> NEm5ZlgzOCEQvHevcWw> Mn7JbY5pcWKrdIOgUW0hS2WubDDTeZJ3cX[jbB?= M4\JS|E4OTZ2M{Oy
U266 MX;jfZRwfG:6aXPpeJkh[XO|YYm= MWSyNEDPxGdxbVy= MVnpcohq[mm2czDNUUBE\WyuIGP1dpZqfmGu NEPtWJYyPzF4NEOzNi=>
MM.1S MmHZSpVv[3Srb36gZZN{[Xl? MXrzeZBxemW|c3XzJHZGT0ZvSX7keYNm\CCHbnTveIhmdGmjbDDD[YxtKFC{b3zp[oVz[XSrb36gZY5lKE2rZ4LheIlwdi5? NHz1cnIyPzF4NEOzNi=>
MM.1R NYDtWZhbTnWwY4Tpc44h[XO|YYm= Mm\0d5VxeHKnc4Pld{BXTUeILVnu[JVk\WRiRX7kc5Rp\WyrYXygR4VtdCCScn;sbYZmemG2aX;uJIFv\CCPaXfyZZRqd25w M3;tdFE4OTZ2M{Oy
Dox40 MWrGeY5kfGmxbjDhd5NigQ>? NH3Nc|B{fXCycnXzd4V{KF[HR1[tTY5lfWOnZDDFcoRwfGinbHnhcEBE\WyuIGDyc4xq\mW{YYTpc44h[W6mIF3p[5JifGmxbj6= M3WwT|E4OTZ2M{Oy
OPM2 MkDySpVv[3Srb36gZZN{[Xl? NXWzeWFve3WycILld5NmeyCYRVfGMWlv\HWlZXSgSY5ld3SqZXzpZYwhS2WubDDQdo9tcW[ncnH0bY9vKGGwZDDNbYdz[XSrb36u NGDxZ3MyPzF4NEOzNi=>
HBMEC NFi2fI1Iem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NUTZUZBkhjFyIN88US=> MkPGSG1UVw>? NIjiSo9KSzVyPUGg{txO NVfx[ZY1OjFyOEG2OVY>
HBMEC MoD6SpVv[3Srb36gZZN{[Xl? M{TqTJ4yKM7:TR?= NXzlTIZUTE2VTx?= MnPFZYJzd2ejdHXzJJRp\SCyaH;zdIhwenmuYYTpc44hd2ZiVlXHSnIzKHerdHig[Il{enWydHnvckBw\iCmb4fud5Rz\WGvIGDMR:6{OQ>? NEDQXpEzOTB6MU[1Oi=>
HBMEC MWXGeY5kfGmxbjDhd5NigQ>? M3i4TJ4yKM7:TR?= NEPmRWpFVVOR M2\COYRqe3K3cITzJJRp\SCUYYOtVoFnNUWUSzDwZZRpf2G7IITodo92\2hiZHXjdoVie2WmIIDoc5NxcG:{eXzheIVlKE2HS{GvNkBidmRiRWLLNU8z NW\5So41OjFyOEG2OVY>
HBMEC NVXqT|dJTnWwY4Tpc44h[XO|YYm= NUPLU4x1hjJyIN88US=> MVTEUXNQ MXXkbZNzfXC2czC1NEUhd2ZidIXi[UBnd3KvYYTpc44h[XRiMTFOwG0> NVrYfFZKOjFyOEG2OVY>
MDA-MB-231 NGLY[5dIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MX7+NVAh|ryP M122W2ROW09? NVLqO|dtUUN3ME21JO69VQ>? NULQOHpPOjFyOEG2OVY>
MDA-MB-231 NF\melVHfW6ldHnvckBie3OjeR?= NGjzXVExNjVizszN NI[3fYVFVVOR MYDpcohq[mm2czD0bIUhTVKNMT:yJJNq\26jbHnu[{Bx[XSqd3H5 NXviSpE2OjFyOEG2OVY>
MDA-MB-231 NEO3NlNHfW6ldHnvckBie3OjeR?= MVe1JO69VQ>? M1PvNmROW09? NGXzS25qdmS3Y3XzJIEh[2WubD3jfYNt\SCjcoLld5Q> M2rVflIyODhzNkW2
J82 NGDR[4pkgXSxdH;4bYNqfHliYYPzZZk> NYKxeJZVhjFyIN88US=> MULEUXNQ MlfkTWM2OD1{ND61O{DPxE1? MmjNNlE2Ojl7MEC=
T24 MonYZ5l1d3SxeHnjbZR6KGG|c3H5 Mm\TglExKM7:TR?= MmX4SG1UVw>? MnHnTWM2OD13Mj60OUDPxE1? MkH1NlE2Ojl7MEC=
HT1376 MnjyZ5l1d3SxeHnjbZR6KGG|c3H5 MUH+NVAh|ryP NEfEXnpFVVOR MljlTWM2OD1{OD6yNUDPxE1? NYnxbm1WOjF3Mkm5NFA>
RT4 M3PGVoN6fG:2b4jpZ4l1gSCjc4PhfS=> NHf6O3R,OTBizszN M1\1eGROW09? NXX1[4I6UUN3ME21MlE1KM7:TR?= NHi5e2QzOTV{OUmwNC=>
CRL1749 MmXOZ5l1d3SxeHnjbZR6KGG|c3H5 NUnhOXc{hjFyIN88US=> NX7HZ4RSTE2VTx?= MoDETWM2OD1{Mj62PUDPxE1? M1jIelIyPTJ7OUCw
HTB9 NIPhWVBkgXSxdH;4bYNqfHliYYPzZZk> NGDXOFZ,OTBizszN NE\2b41FVVOR NF3U[Y1KSzVyPUGxMlg1KM7:TR?= NFHzdXIzOTV{OUmwNC=>
Sup NVq0dmtm[3m2b4TvfIlkcXS7IHHzd4F6 MmLLglExKM7:TR?= MVjEUXNQ NWLyT5Q4UUN3ME21N{4{OiEQvF2= MWmyNVUzQTlyMB?=
HTB3 MXPjfZRwfG:6aXPpeJkh[XO|YYm= NVT0eY1phjFyIN88US=> NWfJ[XpSTE2VTx?= NFnMPXlKSzVyPUG0MlE3KM7:TR?= NFH1O3MzOTV{OUmwNC=>
CEC Mk\USpVv[3Srb36gZZN{[Xl? MnjBglExKM7:Zz;tUC=> MYPEUXNQ MV;kc5dvNXKnZ4XsZZRmeyCYRVfGJIxmfmWucx?= NWrUbXg5OjF4MkC4NlI>
RPE MljXSpVv[3Srb36gZZN{[Xl? NUSxdGo3hjFyIN88[{9uVA>? NEe0[I9FVVOR MXXkc5dvNXKnZ4XsZZRmeyCYRVfGJIxmfmWucx?= MWqyNVYzODh{Mh?=
CEC NGnJeI1HfW6ldHnvckBie3OjeR?= MWj+OUDPxGdxbVy= NEnqfm1FVVOR M4TRdYJtd2OtczDlcoRwfGinbHnhcEBk\WyuIH3p[5JifGmxbh?= M{TySFIyPjJyOEKy
5637 MYnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MUHEUXNQ NGjTZXNKSzVyPUG1MlDjiIoQvF2= MWeyN|g5PzZyNR?=
J82 NUOzVVNPT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M{i3TWROW09? MV;JR|UxRTF6LkVihKnPxE1? NH;wfZIzOzh6N{[wOS=>
5637 MYTBeZRweGijZ4mgZZN{[Xl? M2j6SFIxKM7:TR?= MlfHSG1UVw>? MVr0dolo\2W{czD0bIUh[XW2b4DoZYdq[yCycn;j[ZN{ Mk[0NlM5QDd4MEW=
J82 MlK3RZV1d3CqYXf5JIF{e2G7 MXGyNEDPxE1? NFr5cJFFVVOR NUTYRmJDfHKrZ3fldpMhfGinIHH1eI9xcGGpaXOgdJJw[2W|cx?= MkTKNlM5QDd4MEW=
5637 MnXISpVv[3Srb36gZZN{[Xl? M4TYNlIxKM7:TR?= NXHOO2NxTE2VTx?= NFnq[HFqdmS3Y3XzJIx6e2:|b33hcE1l\XCnbnTlcpQhdmWlcn;zbZM> NV\0[2h4OjN6OEe2NFU>
J82 MYjGeY5kfGmxbjDhd5NigQ>? MVOyNEDPxE1? MkLOSG1UVw>? MUXpcoR2[2W|IHz5d49{d22jbD3k[ZBmdmSnboSgcoVkem:|aYO= MV2yN|g5PzZyNR?=
5637 MmDGSpVv[3Srb36gZZN{[Xl? NWrR[oQ3OjBizszN NHHi[Y5FVVOR NVPVZnY3cW6mdXPld{BtgXOxc3;t[UBidHSncnH0bY9vKGGwZDDpcohq[mm2czDDRkBi[3Srdnn0fS=> M{jLO|I{QDh5NkC1
J82 M2XEZWZ2dmO2aX;uJIF{e2G7 NXj1W2VCOjBizszN NXXzU3BmTE2VTx?= M{HT[4lv\HWlZYOgcJl{d3OxbXWgZYx1\XKjdHnvckBidmRiaX7obYJqfHNiQ1KgZYN1cX[rdIm= Mnq5NlM5QDd4MEW=
KATO-II MkLTS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MXO1JO69VQ>? MXHEUXNQ Mn[3Zoxw[2u|IIDyc4xq\mW{YYTpc44> Mme1NlUzPDl3NUe=
OCUM-2M NWPtUm1zT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MVO1JO69VQ>? NUH4UZdiTE2VTx?= MVjicI9kc3NicILvcIln\XKjdHnvci=> M{XYclI2OjR7NUW3
SNU-16 NXHuWGd3T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MmHEOUDPxE1? MXnEUXNQ NX\JOFM1[myxY3vzJJBzd2yrZnXyZZRqd25? MX:yOVI1QTV3Nx?=
HSC-39 Ml7JS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NGXWW2U2KM7:TR?= NWP5TZBVTE2VTx?= M{TRXIJtd2OtczDwdo9tcW[ncnH0bY9v NHi0V2kzPTJ2OUW1Oy=>
KATO-II Ml\OZ5l1d3SxeHnjbZR6KGG|c3H5 M3;KdZ4yOCEQvF2= M3;MO2ROW09? MXjJR|UxRTBwMTD0c{AzNjBizsztc4wwVA>? Mn3XNlUzPDl3NUe=
OCUM-2M M{nDWoN6fG:2b4jpZ4l1gSCjc4PhfS=> NX3YOotNhjFyIN88US=> M2n0UWROW09? NHjQSVVKSzVyPUCuNUB1dyB{LkCg{txud2xxTB?= NF;lVo0zPTJ2OUW1Oy=>
SNU-16 MWLjfZRwfG:6aXPpeJkh[XO|YYm= MlfGglExKM7:TR?= NGPMR41FVVOR NHzoflVKSzVyPUCuNUB1dyB{LkCg{txud2xxTB?= M1rudVI2OjR7NUW3
HSC-39 NFvFcnpkgXSxdH;4bYNqfHliYYPzZZk> NEnocJd,OTBizszN M4DC[mROW09? MofETWM2OD1yLkGgeI8hOi5yIN88cY9tN0x? M{HFWFI2OjR7NUW3
NIH 3T3 MYjHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MXz+NVAh|ryP MULEUXNQ MWHpcohq[mm2czDj[YxtKGe{b4f0bEBidmRiY3;sc456KG[xcn3heIlwdg>? M4fUb|I2OjR7NUW3
KATO-III MVrGeY5kfGmxbjDhd5NigQ>? Ml2xNUDPxE1? NYj3U|U4TE2VTx?= M2rxWIlv\HWlZYOgZ4VtdC2leXPs[UBienKnc4S= Mm\qNlUzPDl3NUe=
OCUM-2M MUPGeY5kfGmxbjDhd5NigQ>? NVvHOWV3OSEQvF2= MnHnSG1UVw>? M{PYXYlv\HWlZYOgZ4VtdC2leXPs[UBienKnc4S= NUHhVXY{OjV{NEm1OVc>
KATO-III MlHNRZBweHSxc3nzJIF{e2G7 MlX6NUDPxE1? NFLY[3RFVVOR NH;Pb5hqdmS3Y3XzJIFxd3C2b4Ppdy=> M3;0eVI2OjR7NUW3
OCUM-2M NUS0WWFnSXCxcITvd4l{KGG|c3H5 NF3OcYYyKM7:TR?= NHPHdYNFVVOR NHu2VJZqdmS3Y3XzJIFxd3C2b4Ppdy=> NUSxVpd[OjV{NEm1OVc>
KATO-III NWPmO2JLTnWwY4Tpc44h[XO|YYm= NUTVcHZ6OSEQvF2= NFWzcpZFVVOR NYnLd29pcW6qaXLpeJMhTkeIUkKgdIhwe3Cqb4L5cIF1cW:wIHHu[EBld3ewc4Ty[YFuKHOrZ37hcIlv\yCvb3zlZ5Vt\XN? M3XoZ|I2OjR7NUW3

... Click to View More Cell Line Experimental Data

In vivo The mice treated with 30 mg/kg or 100 mg/kg Pazopanib reveals a significant decrease in tumor burden compared with the mice treated with vehicle or 10 mg/kg Pazopanib. Treatment with Pazopanib is well-tolerated and there is no significant difference in the body weight among the mice in each group. [2]

Protocol

Kinase Assay:

[1]

+ Expand

Kinase enzyme assays:

VEGFR enzyme assays for VEGGR1, VEGFR2, and VEGFR3 are run in homogeneous time-resolved fluorescence (HTRF) format in 384-well microtiter plates using a purified, baculovirus-expressed glutathione-S-transferase (GST) fusion protein encoding the catalytic c-terminus of human VEGFR receptor kinases 1, 2, or 3. Reactions are initiated by the addition of 10 μL of activated VEGFR2 kinase solution [final concentration, 1 nM enzyme in 0.1 M HEPES, pH 7.5, containing 0.1 mg/mL bovine serum albumin (BSA), 300 μM dithiothreitol (DTT)] to 10 μL substrate solution [final concentration, 360 nM peptide, (biotin-aminohexyl-EEEEYFELVAKKKK-NH2), 75 μM ATP, 10 μM MgCl2], and 1 μL of titrated Pazopanib in DMSO. Plates are incubated at room temperature for 60 min, and then the reaction is quenched by the addition of 20 μL of 100 mM ethylene diamine tetraacetic acid (EDTA). After quenching, 20 μL HTRF reagents (final concentration, 15 nM Streptavidin-linked allophycocyanin, 1 nM Europium-labeled antiphosphotyrosine antibody diluted in 0.1 mg/mL BSA, 0.1 M HEPES, pH 7.5) is added and the plates incubated for a minimum of 10 min. The fluorescence at 665 nM is measured with a Wallac Victor plate reader using a time delay of 50 μs.
Cell Research:

[1]

+ Expand
  • Cell lines: HUVEC cells
  • Concentrations: 0-10 μM
  • Incubation Time: 1 hour
  • Method:

    Phosphorylation of VEGFR2 is assessed in HUVEC stimulated with VEGF. HUVEC are plated in type-I collagen-coated 10 cm plates in Clonetics EGM-MV medium at 1.0-1.5 × 106 cells/plate. After 24 hours, the confluent cells are serum starved overnight by replacing the growth medium with Clonetics EBM medium containing 0.1% BSA, 500 μg/mL hydrocortisone. Cells are treated with Pazopanib at various concentrations for 1 hour, followed by addition of 10 ng/mL VEGF or vehicle for 10 min. Cells are solubilized in lysis buffer. VEGFR2 is immunoprecipitated using antiflk-1 antibody and analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) followed by Western blotting and detection with antiflk-1 or with antiphosphotyrosine (anti-P-tyr-biotin) antibody. The VEGFR2 phosphorylation level is quantified by densitometry and normalized to the total VEGFR2 level.


    (Only for Reference)
Animal Research:

[2]

+ Expand
  • Animal Models: Immunodeficient mice bearing SYO-1 cells
  • Formulation: --
  • Dosages: 0 mg/kg, 10 mg/kg, 30 mg/kg, or 100 mg/kg
  • Administration: Oral administration
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 17 mg/mL (35.86 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% PEG400+0.5% Tween80+5% propylene glycol
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 473.98
Formula

C21H23N7O2S.HCl

CAS No. 635702-64-6
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03850730 Not yet recruiting Hereditary Hemorrhagic Telangiectasia|Epistaxis Cure HHT|University of North Carolina September 2019 Phase 1|Phase 2
NCT03850964 Not yet recruiting Hereditary Hemorrhagic Telangiectasia|Epistaxis Nosebleed|Anemia Cure HHT September 2019 Phase 2|Phase 3
NCT03850730 Not yet recruiting Hereditary Hemorrhagic Telangiectasia|Epistaxis Cure HHT|University of North Carolina September 2019 Phase 1|Phase 2
NCT03850964 Not yet recruiting Hereditary Hemorrhagic Telangiectasia|Epistaxis Nosebleed|Anemia Cure HHT September 2019 Phase 2|Phase 3
NCT03660930 Not yet recruiting Soft Tissue Sarcoma University of Washington April 1 2019 Phase 1|Phase 2
NCT03660930 Not yet recruiting Soft Tissue Sarcoma University of Washington April 1 2019 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

VEGFR Signaling Pathway Map

VEGFR Inhibitors with Unique Features

Related VEGFR Products4

Tags: buy Pazopanib HCl (GW786034 HCl) | Pazopanib HCl (GW786034 HCl) supplier | purchase Pazopanib HCl (GW786034 HCl) | Pazopanib HCl (GW786034 HCl) cost | Pazopanib HCl (GW786034 HCl) manufacturer | order Pazopanib HCl (GW786034 HCl) | Pazopanib HCl (GW786034 HCl) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID